News

Video

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

Author(s):

Masahiro Tsuboi, MD, National Cancer Center Hospital East

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the updated survival results of the phase 3 ADAURA trial (NCT02511106) in resectable EGFR-mutant non–small cell lung cancer.

Related Videos
Stephen V. Liu, MD
Eytan M. Stein, MD
Vered Stearns, MD
Michael A. Postow, MD
Dr Patel on the Utility of the IPS Test in Solid Tumors
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Related Content
Roy S. Herbst, MD, PhD
December 5th 2024

Immunotherapy Reshapes Perioperative Strategies for Early NSCLC Without Driver Mutations

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

OncLive’s November Roundup of Key FDA Approvals in Oncology
December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24